CDC Health Alert - April 13, 2021 - Recommended Pause of Johnson & Johnson Vaccine Use
As of April 12, 2021, approximately 6.85 million doses of the Johnson & Johnson (J&J) COVID-19 vaccine (Janssen) have been administered in the United States. The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) are reviewing data involving six U.S. cases of a rare type of blood clot in individuals after receiving the J&J COVID-19 vaccine that were reported to the Vaccine Adverse Events Reporting System (VAERS). . . Read more.
The AMA posted a discussion on the new guidance with the FDA's Director of the Center for Biologics Evaluation and Research on April 13.
Update, April 14: The Washington Post (4/14, Sun, Johnson) reports the CDC’s Advisory Committee on Immunization Practices (ACIP) “said Wednesday it wanted more data before deciding whether to resume use of Johnson & Johnson’s single-shot coronavirus vaccine, calling for more information on the risks, cause and frequency of a rare and severe type of blood clot identified so far among six of the 7.5 million people who received the shot.” ACIP held an emergency meeting Wednesday, “a day after federal officials recommended a temporary pause in use of the vaccine.” The committee “agreed to reconvene within a week and a half, acknowledging the urgency of making a decision.”
About this toolkit
Montgomery County physicians are among the first to receive the vaccine, as well as administer it to patients. While guidance continues to evolve and additional details are released each day, the MCMS Immunization Task Force has created this toolkit to provide updates on COVID-19 vaccination distribution in Montgomery County, collate guidance on vaccine handling and storage, promote strong vaccination recommendations to patients, and answer frequently asked questions from physician members.
Six Steps to Prepare for COVID-19 Vaccine Distribution in Your Medical Practice
Understanding & Explaining COVID-19 Vaccines